approval
saveKESIMPTA (OFATUMUMAB) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS
view source ↗Data sources
last refreshed 6mo ago
Found something off?
drug timeline · 8
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalApr 1, 2026 · 233d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 18, 2025 · 459d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalJan 19, 2024 · 1036d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalSep 2, 2022 · 1540d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 20, 2020 · 2283d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 30, 2016 · 3734d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalJan 19, 2016 · 3958d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalApr 17, 2014 · 4600d ago
same company · ±60 days · 6
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 4, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB) — FDA approvalMar 29, 2024
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 29, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalMar 29, 2024
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 29, 2024
- approvalImatinib Mesylate Shilpa: GLEEVEC (IMATINIB MESYLATE) — FDA approvalMar 1, 2024
comments(0)
5-min edit window · permanent after that